Molecular Partners Appoints New Chief Scientific Officer
Molecular Partners AG, a clinical-stage biotech company renowned for developing innovative DARPin therapeutics, has made a significant addition to its executive leadership by appointing Martin Steegmaier, Ph.D., as the new Chief Scientific Officer. This strategic decision aims to bolster the company’s capabilities in delivering next-generation treatment options for cancer.
Bringing Extensive Oncology Experience
Martin Steegmaier's extensive background in oncology makes him a valuable asset. Before joining Molecular Partners, he served as Chief Scientific Officer at SOTIO Biotech, where he was instrumental in developing a diverse pipeline of oncology programs. His experience encompasses senior research roles at notable biotech and pharmaceutical giants like Roche, MorphoSys, and Boehringer Ingelheim.
Leadership and Innovation
As the Chief Scientific Officer, Martin will be pivotal in leading the research organization. His proven track record in oncology drug development underscores the commitment of Molecular Partners to innovating and executing cutting-edge strategies in cancer therapeutics, particularly their focus on DARPin technologies.
Expertise in Drug Development
Martin’s impressive career trajectory includes pivotal roles such as Head of Research at MorphoSys, where he specialized in antibody-based therapeutics, and at Roche, where he advanced the company’s Large Molecule Research initiatives. His comprehensive understanding of cancer therapeutics is expected to enhance Molecular Partners' research-driven approach.
Educational Background
With a solid educational foundation, Martin holds a Ph.D. in biochemistry from the University of Basel and an MBA from the Edinburgh Business School. This combination of scientific expertise and business acumen equips him to navigate the complexities of biotech research and development.
Vision for the Future
Expressing enthusiasm about his new role, Steegmaier emphasized his eagerness to collaborate with the talented team at Molecular Partners. He is committed to furthering the development of DARPin therapeutics, which are designed to address unmet medical needs and provide effective solutions for cancer patients.
About Molecular Partners AG
Molecular Partners AG is dedicated to pioneering DARPin therapeutics aimed at solving medical challenges that traditional drug modalities may struggle to address. The company, founded in 2004, is engaged in multiple stages of drug development with oncology as its primary focus. Molecular Partners operates from dual locations in Zurich, Switzerland, and Concord, Massachusetts, optimizing its global reach and efficacy in developing high-quality therapeutics.
Company Contact Information
For further inquiries, interested parties can reach out to:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
Email: seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
Email: laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Frequently Asked Questions
What role does Martin Steegmaier have at Molecular Partners?
Martin Steegmaier is appointed as the Chief Scientific Officer, overseeing research and development initiatives.
What is Molecular Partners known for?
Molecular Partners is a biotech firm focused on developing DARPin therapeutics for various medical challenges, primarily in oncology.
What experience does Martin bring to the team?
Martin has extensive oncology experience from senior roles in major biotech firms, notably as CSO at SOTIO Biotech.
Where can I find more information about Molecular Partners?
More information is available on the official website at molecularpartners.com.
What is the significance of DARPin therapeutics?
DARPins represent a novel class of therapeutics designed to specifically target and treat cancer, offering new possibilities for patients with high unmet needs.
